Sequencer Products: SEQ ALL
Technologies
Applications
Online Resources
Data Bulletins
Service & Support
Introduction
Newsroom
Doing Business With Us
Creative Club
Shenzhen, CHINA, October 12, 2025 – MGI Tech Co., Ltd. (“MGI”), a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced a milestone step toward globalizing its proprietary CoolMPSTM technology. The Company has signed an exclusive licensing agreement* through its US subsidiaries – MGI US LLC and Complete Genomics Inc. – with Swiss Rockets AG, a Switzerland-based biotech firm complementing its drag and vaccine programs with diagnostics for disease prevention and precision treatment. The agreement is subject to MGI shareholders' meeting by end of October and, upon becoming effective, will grant Swiss Rockers the rights to the research, development, manufacture, and commercialization of exclusive sequencing products based on MGI’s CoolMPS technology and non-exclusive accessory products outside the Asia-Pacific and Greater China regions (i.e., Chinese Mainland, Hong Kong, Macau, and Taiwan).
CoolMPS technology, distinguished by its innovative antibody-based recognition chemistry, represents a breakthrough in sequencing by eliminating DNA “scarring”, a common issue found in conventional long-read methods. It employs nucleotides with natural bases and extension blocks, combined with labeled antibodies that are both base-specific and block-dependent. The CoolMPS method links each nucleotide to multiple fluorescent dye molecules via antibodies, resulting in higher signal intensity and enhanced imaging, delivering highly accurate and reliable long-read performance.
Deployed on MGI’s DNBSEQTM platforms, CoolMPS delivers sequencing reads reaching up to 600 to 700 bases, covering comprehensive genome, transcriptome, and microbiome analyses. Its high fidelity enables crucial applications including early cancer detection and monitoring through whole genome sequencing-based assays, providing scientists, researchers and the wider life science sector with longer, cleaner, and more reliable data at reduced costs.
Under the licensing agreement, Swiss Rockets is granted exclusive rights to MGI’s CoolMPS-related intellectual property, including patents, know-how, and software, to research, develop, manufacture, and commercialize relevant products for global markets excluding Asia-Pacific and Greater China.
* Only effective upon approval at the MGI shareholders' meeting by end of October.
###
About MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.
For more information, please visit https://en.mgi-tech.com/, LinkedIn, X, and YouTube.
About Swiss Rockets AG
Swiss Rockets AG, as both an incubator and accelerator, supports growth of biotech and precision healthcare start-ups, particularly in the field of oncology. It’s portfolio of radioligand therapies, small moleculs and vaccines in pre-clinical and clinical stage, already drew attention of the best global pharmaceutical companies for future partnerships. Swiss Rockets AG was founded by a team consisting of Dr. Vladimir Cmiljanovic, Chief Executive Officer; Dr. Natasa Cmiljanovic, Chief Operating Officer; Manuel Ebner, Dr. Thomas Sander, and Dr. Thomas Staehelin.
